Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2003
03/26/2003EP0932409B1 A method for producing an extract from valeriana officinalis containing high levels of valerenic acid
03/26/2003EP0763026B1 Gastrin and cck antagonists
03/26/2003EP0606248B1 Heteroaryl amines as novel acetyl cholinesterase inhibitors
03/26/2003CN1406236A Process for the preparation of 5-carboxy-phthalide and its use for the production of CITALOPRAM
03/26/2003CN1406227A Aryl fused azapolycy clic compounds
03/26/2003CN1406225A Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
03/26/2003CN1406131A Sympathetic-activating perfume composition
03/26/2003CN1406129A Methods for the treatment of substance abuse
03/26/2003CN1406128A Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
03/26/2003CN1406127A Thiazolium compounds and treatments of disorders associated with protein aging
03/26/2003CN1406126A New sustained release oral formulations
03/26/2003CN1404864A Chinese medicine for treatment of depression
03/26/2003CN1404857A Tea for giving-up smoking
03/26/2003CN1404849A Plaster medicine for giving up smoking
03/26/2003CN1404845A Soporific medicine and its preparation technology
03/26/2003CN1103818C Process for producing phosphatidylserines having having polybasic unsaturated fatty acid and as side chain
03/26/2003CN1103775C Vitronectin receptor antagonists, their preparation and use
03/26/2003CN1103774C Imino-aza-anthracyclinone derivatives for the theatment of amyloidosis
03/26/2003CN1103772C Novel 2,3-disubstituted-4 (3H)-quinazolinone
03/26/2003CN1103770C Quino xaline diones
03/26/2003CN1103590C Use of thiazolidinediones to prevent or delay on set of NIDDM
03/26/2003CN1103589C Method for modulating human sexual response
03/25/2003WO2002026260A1 Preventives/remedies for emotional disorders
03/25/2003US6538151 X-ray diffractogram reflections not coinciding with others; anticonvulsants, analgesics, antipyretics,
03/25/2003US6538149 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo [1,2-g]chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
03/25/2003US6538121 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
03/25/2003US6538036 Method for preventing and treating peripheral neuropathy by administering selegiline
03/25/2003US6538034 Methods of treating or preventing weight gain, obesity, and related disorders
03/25/2003US6538025 Aminoindan derivatives
03/25/2003US6538024 Felbamate derived compounds
03/25/2003US6538017 Anticoagulants; cardiovascular disorders; central nervous system disorders
03/25/2003US6538010 Compounds may be used to treat a variety of other conditions and disease states and reagents for preventing smoking addiction. The present invention also relates to methods and reagents for treating nicotine addiction.
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6538008 Combination of a selective NMDA NR2B antagonist and an opioid analgesic
03/25/2003US6538003 Pyridopyranoazepine derivatives, their preparation and their therapeutic application
03/25/2003US6537995 Heterocyclic carboxamides
03/25/2003US6537991 A method of treating a peripheral neuropathic pain in a warm-blooded animal requiring such treatment which comprises administering to said animal a therapeutically effective amount of an EP1-type prostaglandin receptor antagonist
03/25/2003US6537987 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
03/25/2003US6537969 Nutritional supplement for cerebral metabolic insufficiencies
03/25/2003US6537784 Self-regulated apoptosis of inflammatory cells by gene therapy
03/25/2003US6537775 Gene involved in cadasil, method of diagnosis and therapeutic application
03/25/2003US6537586 Apparatus and method for preparing microparticles
03/25/2003CA2423364A1 Preventives/remedies for emotional disorders
03/25/2003CA2405202A1 Pharmaceutical composition containing two active ingredients for smoking cessation
03/25/2003CA2379005A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
03/25/2003CA2301599C Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
03/25/2003CA2251262C Nucleic acid encoding a nervous tissue sodium channel
03/25/2003CA2234319C Fluoro-substituted adamantane derivatives
03/25/2003CA2232749C Truncated glial cell line-derived neurotrophic factor
03/25/2003CA2201723C Colchicine derivatives and the therapeutical use thereof
03/25/2003CA2149052C Dry mix formulation for bisphosphonic acids
03/25/2003CA2059783C Salts of 2-(2,6-dichloroanilino)-phenylacetic acid, a process for their preparation and their use for pharmaceutical preparations to be applied locally
03/21/2003WO2002026702A1 Phenoxyphenyl alkane sulfonates
03/21/2003WO2002022555A1 Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same
03/21/2003CA2423171A1 Phenoxyphenyl alkane sulfonates
03/20/2003WO2003023404A1 A method of diagnosis and treatment and agents useful for same
03/20/2003WO2003023056A2 Specific markers for multiple sclerosis
03/20/2003WO2003023034A2 Regulation of human tau-tubulin kinase
03/20/2003WO2003023018A2 A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use
03/20/2003WO2003023014A2 Human ion channels
03/20/2003WO2003023008A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003WO2003023001A2 Novel proteins and nucleic acids encoding same
03/20/2003WO2003022877A1 Crystal structure of baff, and use thereof in drug design
03/20/2003WO2003022856A1 Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
03/20/2003WO2003022852A2 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
03/20/2003WO2003022849A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003WO2003022840A1 Pyridine derivatives as raf kinase inhibitors
03/20/2003WO2003022839A1 Tetrahydropyran derivatives and their use as therapeutic agents
03/20/2003WO2003022837A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors
03/20/2003WO2003022836A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors
03/20/2003WO2003022833A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022832A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022820A1 Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
03/20/2003WO2003022814A1 Indole derivatives
03/20/2003WO2003022813A1 Indole derivatives, process for producing the same and drugs containing the same as the active ingredient
03/20/2003WO2003022809A2 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
03/20/2003WO2003022787A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003WO2003022360A2 Thermotherapy via targeted delivery of nanoscale magnetic particles
03/20/2003WO2003022298A2 Use of a protein of the crmp family for treating diseases related to the immune system
03/20/2003WO2003022291A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
03/20/2003WO2003022290A1 Medicinal compositions for diabetic neuropathy
03/20/2003WO2003022285A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003WO2003022283A1 Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
03/20/2003WO2003022277A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
03/20/2003WO2003022276A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003WO2003022273A1 Methods of treating cytokine mediated diseases
03/20/2003WO2003022271A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease
03/20/2003WO2003022269A1 Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
03/20/2003WO2003022266A1 Hypoestoxides, derivatives and agonists thereof for use as inhibitors of angiongenesis
03/20/2003WO2003022259A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003WO2003022246A1 Treating effects of excessive reactive oxygen species
03/20/2003WO2003022218A2 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
03/20/2003WO2003022217A2 Treatment of excessive radiation (e.g. sunburn) exposure
03/20/2003WO2003022216A2 Biaryl substituted purine derivatives as potent antiproliferative agents
03/20/2003WO2003004046A3 Use of xaa-pro peptidases for the treatment of substance p-related disorders
03/20/2003WO2003002175A3 Enhanced systemic absorption of intradermally delivered substances
03/20/2003WO2002102808A3 (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR
03/20/2003WO2002102344A3 No-synthase inhibitor and use thereof
03/20/2003WO2002100836A8 Compounds, compositions and methods for modulating beta-amyloid production
03/20/2003WO2002098363A3 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
1 ... 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 ... 1833